Rambaldi, Alessandro http://orcid.org/0000-0002-3739-7502
Iurlo, Alessandra http://orcid.org/0000-0002-4401-0812
Vannucchi, Alessandro M.
Noble, Richard
von Bubnoff, Nikolas
Guarini, Attilio
Martino, Bruno
Pezzutto, Antonio http://orcid.org/0000-0002-3246-4470
Carli, Giuseppe
De Muro, Marianna
Luciani, Stefania
McMullin, Mary Frances http://orcid.org/0000-0002-0773-0204
Cambier, Nathalie
Marolleau, Jean-Pierre
Mesa, Ruben A.
Tibes, Raoul
Pancrazzi, Alessandro
Gesullo, Francesca
Bettica, Paolo
Manzoni, Sara
Di Tollo, Silvia
Funding for this research was provided by:
This study was funded by Italfarmaco S.p.A.
Article History
Received: 15 October 2019
Revised: 6 December 2019
Accepted: 29 January 2020
First Online: 11 February 2020
Compliance with ethical standards
:
: AR has received honoraria for consultancy, and travel support from Italfarmaco, Gilead, Amgen, Novartis, Pfizer, Celgene, Sanofi, Astellas and Roche. AI has received speaker honoraria from Novartis, Pfizer and Incyte. AMV has received honoraria for advisory board participation from Novartis, Celgene, Incyte, CTI and Italfarmaco, and for lectures from Novartis, and CTI. N.v.B. received research funding from Novartis. MFM has received honoraria and has attended advisory boards with Novartis, and has received honoraria from Celgene. RAM has received honoraria as a consultant to Novartis, Sierra Oncology, and La Jolla Oncology, and research support from Incyte, Genentech, Celgene, CTI, and Abbvie. RT has advised and received honoraria from Italfarmaco. PB, SM, and SDT are employees of Italfarmaco SpA, the sponsor of the study. RN, AG, BM, AP, GC, MDM, SL, NC, J-PM, APancrazzi, FG have no conflicts to disclose.